ChemoCentryx, which is developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo, will see its quiet period end on 3/19/12. On 2/8/12, the company raised $45.0 million by offering 4.5 million shares at $10.00, below the range of $14.00 to $16.00. J.P. Morgan and Citi acted as lead managers on the deal.
